ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter

RANCHO CORDOVA, Calif., April 13, 2011 /PRNewswire/ —
ThermoGenesis Corp. (NASDAQ:
KOOL), a leading supplier of innovative products and services
that process and store adult stem cells, said today that its
Res-Q™60 BMC System (Res-Q) has been registered by the
Central Drugs Standard Control Organization of India (CDSCO),
allowing its commercial sale in the country. Res-Q is a point of
care system used for the preparation of cell concentrates,
including stem cells from bone marrow aspirate.

“This is a major regulatory milestone for the Company and our
market expansion strategy,” said J. Melville Engle, Chairman and
Chief Executive Officer of ThermoGenesis. “We appreciate the
efforts of TotipotentSC (MK Alliance, Inc.), our South Asian
partner, in achieving this approval and look forward to working
with them on the commercial launch of the product,” he added.

The Company said it is ready to initiate the market roll out for
Res-Q in India and expects to record initial revenues from the
launch during the current quarter, supported by existing clinical
trial programs also managed through Totipotent’s clinical
division.

According to the MK Alliance Chairman, Kenneth L. Harris, “New
stem cell technologies, such as Res-Q, are being adopted at a
gradual but growing rate in India – a macro market which
enjoyed double digit growth despite a challenging economic
environment. We believe in cellular medicine and that this device
can have an important impact on the clinical cell therapy platform
we make available to the medical community.”

During the last quarter, Totipotent initiated enrollment in a
clinical evaluation to establish the safety and efficacy of Res-Q
for use in treating patients with Critical Limb Ischemia (CLI).
Enrollment in the study is expected to be completed in the near
future. This phase 1b trial is one among several the group

‘/>”/>

SOURCE